ORPHA:71271
Split hand-split foot-deafness syndrome
Also known as: Split hand-split foot-hearing loss syndrome
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
20
28.7th percentile
Trials
0
Interventional, condition-specific
Researchers
158
Distinct authors in sample
Gene link
DLX5
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Split hand - split foot - deafness is an extremely rare genetic syndrome reported in a few families to date and characterized clinically by split hand/split foot (SHFM) and mild to moderate sensorineural hearing loss, sometimes associated with cleft palate and intellectual deficit.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009080
- MeSH:C565647
- OMIM:220600
- UMLS:C1857344
Additional Mondo synonyms (3)
SHFM1D · split hand-foot malformation 1 with sensorineural hearing loss · split-hand/foot malformation 1 with sensorineural hearing loss
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — DLX5
- LiteraturePresent
20 matched papers (11 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DLX5).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
20
20 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
20 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
11 in the last 10 years · high confidence · 28.7th percentile (publications denominator)
Phrase hits: 20 · MeSH hits: 0
Who's working on it?
158
Distinct author names in 20 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Jamsheer A2 papers · 2023
Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland
Papers in Europe PMC - 02Spielmann M2 papers · 2023
Institute for Medical Genetics and Human Genetics, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, 13353, Germany
Papers in Europe PMC - 03Aglan MS1 paper · 2026
Center of Excellence of Human Genetics, National Research Centre, Cairo, Egypt.
Papers in Europe PMC - 04Ahituv N1 paper · 2012Papers in Europe PMC
- 05Alemu R1 paper · 2026
Archie's Cochlear Implant Laboratory, Hospital for Sick Children, Toronto, Ontario, Canada.
Papers in Europe PMC - 06Altmüller J1 paper · 2021
Cologne Center for Genomics, University of Cologne, Cologne, Germany.
Papers in Europe PMC - 07Asmus F1 paper · 2007
Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Center of Neurology, University of Tuebingen, Tuebingen, Germany. friedrich.asmus@uni-tuebingen.de
Papers in Europe PMC - 08Bae JG1 paper · 2014
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Deagu, Korea.
Papers in Europe PMC - 09Bartels H1 paper · 2026
Archie's Cochlear Implant Laboratory, Hospital for Sick Children, Toronto, Ontario, Canada.
Papers in Europe PMC - 10Bergonzini P1 paper · 2014Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Split hand-split foot-deafness syndrome" OR "Split hand-split foot-hearing loss syndrome" OR "SHFM1D" OR "split hand-foot malformation 1 with sensorineural hearing loss" OR "split-hand/foot malformation 1 with sensorineural hearing loss"
MeSH descriptor terms unioned into the query: Split-Hand-Foot Malformation With Sensorineural Hearing Loss
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Split hand-split foot-deafness syndrome" OR "Split hand-split foot-hearing loss syndrome" OR "SHFM1D" OR "split hand-foot malformation 1 with sensorineural hearing loss" OR "split-hand/foot malformation 1 with sensorineural hearing loss" OR "Split-Hand-Foot Malformation With Sensorineural Hearing Loss" OR "DLX5"
Recall-expansion terms: DLX5
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T01:39:35.574Z